CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates novel ruthenium-based compounds as potential treatments for ovarian cancer, particularly in cases resistant to standard therapies. It aims to enhance drug delivery systems to improve the efficacy and reduce toxicity of these compounds in patient-derived models.
Nearly 250,000 women are diagnosed each year with ovarian cancer around the world, resulting in 140,000 deaths.
High-grade epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer, ranking fifth overall in cancer deaths.
The majority of women have widespread intra-abdominal disease at the time of diagnosis, and the 5-year survival rate for these women is only about 40% after receiving standard therapy.
Currently, the standard first-line treatment for ovarian cancer consists of surgica…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
